The prognosis of advanced NSCLC has dramatically improved with the advent of nivolumab [2,3], pembrolizumab [4,5] (anti-programmed cell death 1 [PD-1] antibodies), and atezolizumab [6] (anti-programmed cell death ligand 1 [PD-L1] antibodies). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.